Cerebrospinal fluid markers and magnetic resonance imaging lesion volume predicting relapse in canine meningoencephalitis of unknown origin

脑脊液标志物和磁共振成像病灶体积预测犬不明原因脑膜脑炎的复发

阅读:1

Abstract

INTRODUCTION: Meningoencephalitis of unknown origin (MUO) is a potentially lethal neurological disease in dogs with a high relapse rate. Prognostic factors for relapse based on neurological examination, magnetic resonance imaging (MRI), or cerebrospinal fluid (CSF) examination are inconsistently reported. METHODS: This retrospective single center study included 35 dogs with MUO. Brain MRI, CSF findings, clinical signs at diagnosis and during follow-up MRI (routine or relapse-related) were analyzed. Lesion volumes were calculated using the Cavalieri method. Relapse predictors were evaluated for routine follow- up MRI examinations using logistic regression and ROC/AUC. RESULT: Only higher CSF albumin (p = 0.0413) and lymphocyte proportion (p = 0.0288) at routine follow-up examination were predictive of future relapse. ROC analyses identified thresholds of 9.64 mg/dl for CSF albumin (AUC: 0.75; sensitivity 86.7%, specificity 61.1%) and 74.0% for CSF lymphocytes (AUC 0.76; sensitivity 66.7%, specificity 64.3%). Total lesion volume and volume of contrast-enhancing lesions decreased after treatment and increased again at relapse. Increased lesion volume or normal MRI on routine follow-up MRI did not reliably predict future relapse, although increased lesion volume in T1-weighted contrast enhancement and Fluid-attenuated inversion recovery (FLAIR) was observed at or after relapse. Lesion volume, lesion number, and lesion localization in different sequences was associated with neurodisability scale (NDS) and epileptic seizures. DISCUSSION: In this study, CSF albumin and lymphocyte proportion were identified as predictors of future relapse. Routine follow-up MRI was not predictive of future relapse, but useful for detection of an active inflammation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。